Proximity Work in Family Medicine Groups : the Impact of Pharmacists

Health Services Clinical Trial

— FMG  

Official title:

Proximity Work in Family Medicine Groups : the Impact of Pharmacists

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02963636
• Other study ID #: 106238
• Status: Completed
• Phase: N/A
• First received: February 17, 2016
• Last updated: November 14, 2016
• Start date: August 2015
• Est. completion date: April 2016

Study information

• Verified date: November 2016
• Source: Laval University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The project objective is to evaluate the impact of the recent addition of pharmacists within family medicine groups (FMGs) on organizational and clinical parameters. The process by which changes occur and the level of pharmacists' activities will also be assessed. The ultimate goal of the project is the development of an accompanying guide to facilitate the work of the pharmacist in monitoring complex patients in primary care medical clinics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Willing to meet with the pharmacist and;

• Consuming drugs of four or more different pharmacological classes or having to take at least four doses per day and;

• aged 70 or over with at least two criteria of vulnerability or aged less than 70 with at least 3 criteria of vulnerability or had a recent loss of autonomy or in post- hospitalization with medication changes in the hospital.

Exclusion Criteria:

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Health Services

Intervention

Other:
• Pharmacist clinical intervention
Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.

Locations

Country	Name	City	State
Canada	CIUSSS de la Capitale-Nationale	Québec	Quebec

Sponsors (4)

Lead Sponsor	Collaborator
Laval University	Fonds de la Recherche en Santé du Québec, McGill University, Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of drug related problems		3 to 6 months	No
Secondary	Regimen complexity	Medication regimen complexity index (MRCI)	3 to 6 months	No
Secondary	Medication adherence	Proportion of days covered (PDC)	3 to 6 months	No
Secondary	Quality of care provided by the clinical team (pharmacists, doctors, nurses, etc.)	Quality indicators (proposed by INESSS)	3 to 6 months	No